Skip to main content

CORRECTION article

Front. Immunol., 08 February 2024
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | https://doi.org/10.3389/fimmu.2024.1379325

Corrigendum: Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells

This article is a correction to:

  1. Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells

    1. Read original article
Zhenyu Wei*Zhenyu Wei1*Jiayu XuJiayu Xu1Chengkui Zhao,Chengkui Zhao1,2Min ZhangMin Zhang1Nan Xu,Nan Xu2,3Liqing Kang,Liqing Kang2,3Xiaoyan Lou,Xiaoyan Lou2,3Lei Yu,*Lei Yu2,3*Weixing Feng*Weixing Feng1*
  • 1Intelligent Systems Science and Engineering College, Harbin Engineering University, Harbin, China
  • 2Shanghai Unicar-Therapy BioMedicine Technology Co., Ltd, Shanghai, China
  • 3School of Chemical and Molecular Engineering, East China Normal University, Shanghai, China

A Corrigendum on
Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells

By Wei Z, Xu J, Zhao C, Zhang M, Xu N, Kang L, Lou X, Yu L and Feng W (2023) Front. Immunol. 14:1273507. doi: 10.3389/fimmu.2023.1273507

In the published article, there was an error in Supplementary and the names of the patients were erroneously included. The names have been removed from the supplementary materials to protect the anonymity and identity of the patients.

The supplementary material has been updated in the original article.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: CAR-T cell therapy, cytokine release syndrome (CRS), biomarker, prediction, decision tree

Citation: Wei Z, Xu J, Zhao C, Zhang M, Xu N, Kang L, Lou X, Yu L and Feng W (2024) Corrigendum: Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells. Front. Immunol. 15:1379325. doi: 10.3389/fimmu.2024.1379325

Received: 31 January 2024; Accepted: 01 February 2024;
Published: 08 February 2024.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2024 Wei, Xu, Zhao, Zhang, Xu, Kang, Lou, Yu and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Zhenyu Wei, 952376687@hrbeu.edu.cn; Weixing Feng, Fengweixing@hrbeu.edu.cn; Lei Yu, ylyh188@163.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.